US Market Access and Commercial Execution

Tehnopol, room Saturn, Tallinn

Turning US market opportunity into commercially viable revenue

The US healthcare market offers enormous opportunities for European healthtech and life science companies. But success requires more than understanding regulatory pathways, identifying potential customers, or demonstrating clinical value.

The real challenge is translating that value into a commercially sustainable business: who will pay, why will they pay, what must happen before a purchase, and how can companies reach revenue without exhausting their capital?

Following the Health3-2-1 workshops hosted by Swecare in Stockholm, Lund, and Business Turku earlier this year, Tehnopol is bringing the third installment of the series to Tallinn.

Led by Elizabeth Jennings, Managing Partner of Venture Atlas Labs, this advanced, interactive workshop moves beyond US market-entry fundamentals into the economics, commercial agreements, institutional purchasing decisions, and partnerships that determine whether companies can actually generate revenue.

It is designed for companies actively preparing to enter or expand in the US, as well as those evaluating whether their commercial assumptions are realistic.

Previous participation is not required. The workshop builds on earlier sessions while providing the context necessary for newcomers.

The workshop uses real-world examples, practical exercises, commercial case studies, and discussion rather than relying on theoretical market-entry frameworks.

What will we cover?

Thursday, 26 November — Commercializing for value and capital efficiency

09:00–10:30 US market structure and economic buyers

10:30–10:45 Break

10:45–12:15 Reimbursement and payer economics

12:15–13:15 Lunch

13:15–14:45 Value-based care and contracting

14:45–15:00 Break

15:00–16:30 Pricing, procurement and institutional adoption

16:30–17:00 Discussion and Q&A

Friday, 27 November — Strategic partnerships and commercial execution

09:00–10:30 Strategic partnerships, licensing and distribution

10:30–10:45 Break

10:45–12:15 Sales strategy, compliance and six-month planning

12:15–13:00 Lunch

13:00–16:00 Pre-booked individual company consultations

Individual company sparring

Friday afternoon will be reserved for pre-booked 1:1 sessions with Elizabeth to discuss company-specific market entry challenges, commercial assumptions, positioning, partnerships, and next steps.

Would you like to book a 1:1 session with Jennings? Please contact Project Manager Mariann Uudmäe at [email protected].

Meet the expert

Elizabeth Jennings is Managing Partner at Venture Atlas Labs and has 16 years of experience in international healthcare technology commercialization and investment, spanning 28 countries.

Her background includes startup and executive leadership, venture investment, healthcare economics, policy, and advisory work with international innovation ecosystems. She has authored three guidebooks on US healthcare commercialization and economics for Denmark and New Zealand and regularly works with Nordic and Baltic healthtech companies preparing for US expansion.

Elizabeth previously led the Health3-2-1 workshops in Stockholm, Lund, and Turku in 2026.

Practical information

Dates: 26–27 November 2026

Location: Tehnopol, Tallinn

Format: In-person, English-language workshop with interactive instruction, exercises, and individual sparring

Organized by: Tehnopol within the Health3-2-1 programme, in collaboration with Swecare and Business Turku.

Selection

US Market Access and Commercial Execution

0.00 €

Free

Contacts

Ticket #1

*If you do not wish to appear in photographs or video recordings, please inform the photographer at the event.


Payment method

Banks and credit cards
Invoice and bank transfer

Tehnopol, room Saturn • Teaduspargi 6/1, 12618 Tallinn, Harju maakond, Estonia

Google Map of Teaduspargi 6/1, 12618 Tallinn, Harju maakond, Estonia

Science Park Tehnopol

events@tehnopol.ee

View all events